Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers
- 1 March 2011
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 32 (3) , 168-174
Abstract
Objective.To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers.Methods.Ten healthy male volunteers were assigned into a 2‐sequence, 3‐period pharmacokinetic interaction study. In phase 1, all subjects were randomly assigned to receive 500 mg of ciprofloxacin alone and 200 mg of itraconazole alone twice daily for 7 days with a 14 day wash‐out period in a crossover design. Phase 2 was performed 14 days after finishing phase 1, all subjects received 500 mg of ciprofloxacin in combination with 200 mg of itraconazole twice daily for 7 days. Ciprofloxacin and itraconazole pharmacokinetics were studied and adverse effects noted.Results.Ciprofloxacin significantly increased theCmaxandAUC0 − ∞of itraconazole by 53.13% and 82.46%, respectively. The half‐life andCLof itraconazole were not changed significantly. The combination of itraconazole and ciprofloxacin could therefore result in an increase in adverse drug reactions. Conversely, itraconazole had no significant effect on the pharmacokinetics of ciprofloxacin.Conclusion.Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 15 references indexed in Scilit:
- Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacinBiopharmaceutics & Drug Disposition, 2007
- Lack of inhibitory effects of several fluoroquinolones on cytochrome P‐450 3A activities at clinical dosage in dogsJournal of Veterinary Pharmacology and Therapeutics, 2007
- The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteersBiopharmaceutics & Drug Disposition, 2005
- Does inhibition of P-glycoprotein lead to drug–drug interactions?Toxicology Letters, 2005
- ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITIONDrug Metabolism and Disposition, 2004
- Midazolam α‐Hydroxylation by Human Liver Microsomesin vitro: Inhibition by Calcium Channel Blockers, Itraconazole and KetoconazoleBasic & Clinical Pharmacology & Toxicology, 1999
- Active intestinal elimination of ciprofloxacin in rats: modulation by different substratesBritish Journal of Pharmacology, 1999
- CiprofloxacinDrugs, 1996
- Micro-scale method for itraconazole in plasma by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal functionAntimicrobial Agents and Chemotherapy, 1987